Overview

A First-in-human, Phase I, Open-label, Multicenter Study of NM1F Administered as Monotherapy and in Combination With Pembrolizumab to Patients With Advanced Solid Tumors.

Status:
Not yet recruiting

Trial end date:
2026-09-01

Target enrollment:

Participant gender:

Summary

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/Pharmacodynamics, and Antitumor Activity of NM1F as Monotherapy and in Combination with Pembrolizumab in Subjects with Locally Advanced/Metastatic Solid Tumors

Phase:

Phase 1

Details

Lead Sponsor:

Hefei TG ImmunoPharma Co., Ltd.

Treatments:

Pembrolizumab